Oruka Therapeutics, Inc. (XETR:HQ1) Financings

Oruka Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Made bigger: about US$700.4M · US$72.5 a share · Leerink Partners +5
Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Goldman Sachs & Co. LLC (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Apr 28, 2026
Private placement of common stock and pre-funded warrants
Closed: US$180M raised · US$15 a share · Jefferies +3
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead)
Buyers: Viking Global Investors (led the PIPE financing); Affinity Healthcare Fund; Blackstone Multi-Asset Investing; Commodore Capital; Cormorant Asset Management; Deep Track Capital; Fairmount; Great Point Partners, LLC; Palo Alto Investors, LP; Perceptive Advisors; Surveyor Capital; Venrock Healthcare Capital Partners
Use of proceeds: Extend cash runway over one year past three Phase 2 readouts (ORKA-001 Phase 2a and 2b, ORKA-002 Phase 2)
Nov 12, 2025

Read by 6ix AI from the company's releases